Summary
The objectives of this study were to establish if, and to what extent, benzbromarone affects allopurinol/oxypurinol kinetics, and to compare the uric acid lowering capabilities of Allomaron® (allopurinol 100 mg plus benzbromarone 20 mg) with the effects of allopurinol alone in patients with confirmed gout.
We studied 14 adult men in an open randomized cross-over study. After a 14 day run-in period with Zyloprim® (2×100 mg allopurinol tablets in the morning), the patients were randomly allocated to morning doses of either Allomaron® (2 tablets) or Zyloprim® (2 tablets). Seven days later cross-over was effected and the alternative treatment was taken for a further 7 days.
On days 7 and 14 the patients came into hospital and venous blood samples were taken over 24 h for allopurinol and oxypurinol assays by HPLC. Serum uric acid was determined on days -14, 1, 7, and 14.
Benzbromarone lowered plasma oxypurinol concentrations (Allomaron®/Zyloprim® mean ratio of AUC0→24 was 59%; 95% confidence interval 54–64%), but did not affect plasma allopurinol concentrations.
Despite this pharmacokinetic interaction of benzbromarone with allopurinol, resulting in lower plasma concentrations of oxypurinol, Allomaron® was superior to allopurinol alone in lowering serum uric acid, probably because of the added uricosuric effect of benzbromarone.
Similar content being viewed by others
References
Arntz HR, Dreykluft HR, Leonhardt H (1979) Wirkung Harnsäuresenkender Medikamente in niedriger Dosierung. Fortschr Med 97: 1212–1214
Breithaupt H, Tittel M (1982) Kinetics of allopurinol after single intravenous and oral doses: noninteraction with benzbromarone and hydrochlorothiazide. Eur J Clin Pharmacol 22: 77–84
Elion GB, Kovensky A, Hitchings GH, Metz E, Rundles RW (1966) Metabolic studies of allopurinol, an inhibitor of xanthine oxidase. Biochem Pharmacol 15: 863–880
Elion GB, Yü T-F, Gutman AB, Hitchings GH (1968) Renal clearance of oxypurinol, the chief metabolite of allopurinol. Am J Med 45: 69–77
Gardner MJ, Altman DG (1986) Confidence intervals rather than P values: estimation rather than hypothesis testing. Br Med J 292: 746–750
Hande K, Reed E, Chabner B (1978) Allopurinol kinetics. Clin Pharmacol Ther 23: 598–605
Löffler W, Gröbner W (1982) Kombinierte Behandlung der Hyperurikämie. In: Zöllner N (Hrsg) Hyperurikämie und Gicht 5. Springer, Berlin Heidelberg New York
Matzkies F, Berg G (1976) Behandlung der Hyperurikämie mit einer Kombination von Allopurinol und Benzbromaron. Dtsch Med Wochenschr 101: 1568–1570
Mertz DP (1976) Vermindertes Risiko bei der Behandlung von Gicht und Hyperurikämie. Dtsch Med Wochenschr 101: 1288–1292
Mertz DP (1977) Gicht — Neuere Ergebnisse zur Pathogenese, Diagnose und Therapie. Hippokrates 48: 340–350
Mertz DP, Loewer H (1979) Wirkungsprofil der Harnsäuresenkung bei Höherdosierung von Allopurinol. Dtsch Med Wochenschr 104: 324–325
Steinijans VW, Diletti E (1983) Statistical analysis of bioavailability studies: parametric and nonparametric confidence intervals. Eur J Clin Pharmacol 24: 127–136
Walter-Sack J, Gröbner W, Zöllner N (1979) Verlauf der Oxipurinol-Spiegel im Plasma nach akuter und chronischer Gabe von Allopurinol in verschiedenen galenischen Zubereitungen. Arzneimittelforschung (Drug Res) 29: 839–842
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Müller, F.O., Schall, R., Groenewoud, G. et al. The effect of benzbromarone on allopurinol/oxypurinol kinetics in patients with gout. Eur J Clin Pharmacol 44, 69–72 (1993). https://doi.org/10.1007/BF00315283
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1007/BF00315283